Quick answers
- What is Processed nerve allograft used for?
- The FDA-approved label (Avance Nerve Graft, Axogen Corporation, January 23, 2026) says: “AVANCE is an acellular nerve scaffold indicated for the treatment of adult and pediatric patients aged one month and older with: • Sensory nerve discontinuity (≤25 mm). • Sensory nerve discontinuity (>25 mm). …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Processed nerve allograft have a boxed warning?
- No. None of the 1 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Processed nerve allograft?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Processed nerve allograft been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Processed nerve allograft?
- 1 company lists prescription products of Processed nerve allograft in the FDA NDC Directory, including Axogen Corporation.
What Processed nerve allograft is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
AVANCE is an acellular nerve scaffold indicated for the treatment of adult and pediatric patients aged one month and older with: • Sensory nerve discontinuity (≤25 mm). • Sensory nerve discontinuity (>25 mm). …
— FDA label: Avance Nerve Graft, Axogen Corporation, effective January 23, 2026. Read the full label on DailyMed →
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
Forms and how it is given
| Dosage forms | Implant |
|---|---|
| Route | Soft tissue |
| Prescription products | 16 in the FDA NDC Directory |
| Brand names | Avance Nerve Graft |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Axogen Corporation16 products
FDA approval history
- BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| BLA125816 | — | Date not on file | — |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 2749421, 2749427 |
|---|---|
| SPL set ID of the quoted label | e50d90fa-83ef-4d1b-9691-2b9c7bbdc2ae |
| FDA labels (SPL) | 1 |
| FDA applications | BLA125816 |
| Active ingredients (FDA) | HUMAN PERIPHERAL NERVE TISSUE |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Avance Nerve Graft, Axogen Corporation, effective January 23, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →